Abstract Number: 2814 • 2017 ACR/ARHP Annual Meeting
Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE
Background/Purpose: Plasmacytoid dendritic cells are considered the main source of pathogenic IFN in SLE. However, recent work found that elevated serum type I IFN protein…Abstract Number: 2817 • 2017 ACR/ARHP Annual Meeting
Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero
Background/Purpose: Women with Sjögren’s syndrome and autoantibodies against Ro/SSA are at risk for pregnancy complications, including neonatal lupus erythematosus (NLE) and a congenital heart block…Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting
BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…Abstract Number: 1007 • 2016 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 1 Is the Key Driver of Inflammasome Activity in Systemic Lupus Erythematosus
Background/Purpose: The inflammasome complex has recently emerged as a driver of organ damage in systemic lupus erythematosus (SLE). This complex, via its enzymatic subunit caspase-1,…Abstract Number: 1826 • 2016 ACR/ARHP Annual Meeting
STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE
Background/Purpose: In our previous work, we reported a link between interferon alpha inhibition and decreased expression of B cell activation genes in ex vivo whole…Abstract Number: 1830 • 2016 ACR/ARHP Annual Meeting
The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus
Background/Purpose: Although the increased expression of type I interferon (IFN)-inducible genes, called “IFN signature”, has been suggested to have important roles in the pathogenesis of…Abstract Number: 2012 • 2016 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
Background/Purpose: Preliminary validation of a Lupus Low Disease Activity State (LLDAS) definition has demonstrated that LLDAS attainment is associated with reduced damage accrual in patients…Abstract Number: 2013 • 2016 ACR/ARHP Annual Meeting
BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon…Abstract Number: 2806 • 2016 ACR/ARHP Annual Meeting
A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
Background/Purpose: Type I interferon has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about its role in other…Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…Abstract Number: 1645 • 2014 ACR/ARHP Annual Meeting
Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients
Background/Purpose: Elevated expression of interferon(IFN)-regulated genes in peripheral blood cells has been reported in systemic lupus erythematosus (SLE) patients and is known as the IFN…Abstract Number: 1609 • 2014 ACR/ARHP Annual Meeting
Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease
Background/Purpose: Type I interferons play a role in the pathogenesis of systemic lupus erythematosus (SLE), but their mechanisms of action are still not fully understood.…Abstract Number: 1618 • 2014 ACR/ARHP Annual Meeting
Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties
Background/Purpose Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with the development of auto-antibodies particularly against nuclear antigens. Previous studies have revealed the possible…Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…Abstract Number: 1741 • 2013 ACR/ARHP Annual Meeting
Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Background/Purpose: The interferon alpha (IFN) gene signature is frequent in SLE (~50% of patients) and important in pathogenesis. However, multiple studies have found that the…
ACR Meeting Abstracts